会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 81. 发明申请
    • Plasma etching apparatus and plasma etching method
    • 等离子体蚀刻装置和等离子体蚀刻方法
    • US20060169671A1
    • 2006-08-03
    • US11072305
    • 2005-03-07
    • Go MiyaJunichi TanakaSeiichiro KannoAkitaka MakinoMotohiko Yoshigai
    • Go MiyaJunichi TanakaSeiichiro KannoAkitaka MakinoMotohiko Yoshigai
    • C23F1/00H01L21/306
    • H01L21/67069H01J37/3244H01J37/32449H01L21/32137
    • To provide a plasma etching apparatus that achieves a high in-plane uniformity of the CD shift. A plasma etching apparatus includes: a process chamber 26 in which a plasma etching process is performed on a process target object 1; A first gas supply source 100 for supplying a first process gas; a second gas supply source 110 for supplying a second process gas; a first gas introduction area 42-1 having a first gas introduction port for introducing the first process gas into the process chamber 26; a second gas introduction area 42-2 having a second gas introduction port 3 for introducing the second process gas into the process chamber 26; flow controllers 102, 113 for adjusting the flow rates of the process gasses; and a gas flow divider 120 for dividing the process gas into a plurality of gas flows, in which the first gas introduction port and the second gas introduction port are provided substantially in the same plane, and the first gas introduction area 42-1 and the second gas introduction area 42-2 are separated from each other.
    • 提供一种实现CD偏移的高平面内均匀性的等离子体蚀刻装置。 等离子体蚀刻装置包括:对处理对象物1进行等离子体蚀刻处理的处理室26; 用于供应第一处理气体的第一气体供应源100; 用于供应第二处理气体的第二气体供应源110; 具有用于将第一处理气体引入到处理室26中的第一气体导入口的第一气体导入区域42-1; 具有用于将第二处理气体引入到处理室26中的第二气体导入口3的第二气体导入区域42-2; 流量控制器102,113,用于调节过程气体的流量; 以及用于将处理气体分成多个气流的气体分流器120,其中第一气体导入口和第二气体导入口基本上设置在同一平面上,第一气体导入区域42-1和 第二气体导入区域42-2彼此分离。
    • 86. 发明申请
    • PLASMA PROCESSING APPARATUS AND PROCESSING METHOD
    • 等离子体加工设备和加工方法
    • US20050189070A1
    • 2005-09-01
    • US10875213
    • 2004-06-25
    • Junichi TanakaHiroyuki KitsunaiHideyuki YamamotoShoji IkuharaAkira Kagoshima
    • Junichi TanakaHiroyuki KitsunaiHideyuki YamamotoShoji IkuharaAkira Kagoshima
    • H01L21/3065C23F1/00H01L21/00H01L21/26H01L21/306
    • H01L21/67103H01J37/32522H01L21/67248
    • The present invention provides a plasma processing apparatus and processing method capable of maintaining a constant processing profile. The plasma processing apparatus for providing a plasma processing to a wafer placed in a processing chamber comprises a processing vessel 1a constituting the processing chamber 1, process gas supply devices 3, 4 for supplying processing gas to the processing chamber 1, and a plasma generating means 2 for generating plasma by supplying electromagnetic energy to the processing chamber and dissociating the process gas supplied to the processing chamber, wherein the apparatus further comprises a processing chamber surface temperature control unit 15 for controlling the inner surface temperature of the processing chamber, the control unit controlling the temperature by heating the inner surface of the processing chamber by generating plasma in the chamber for a predetermined processing time based on a processing history after terminating a cleaning process and prior to performing the wafer processing.
    • 本发明提供一种能够保持恒定的处理轮廓的等离子体处理装置和处理方法。 用于向放置在处理室中的晶片提供等离子体处理的等离子体处理装置包括构成处理室1的处理容器1 a,用于向处理室1供应处理气体的处理气体供应装置3,4以及等离子体产生 用于通过向处理室供应电磁能并解离供给到处理室的处理气体来产生等离子体的装置2,其中该装置还包括处理室表面温度控制单元15,用于控制处理室的内表面温度,控制 通过在终止清洁处理之后和在执行晶片处理之前基于处理历史在腔室中产生等离子体预定处理时间来加热处理室的内表面来控制温度的单元。
    • 87. 发明授权
    • Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
    • 具有抗肿瘤活性的羟基和氨基取代的四氢呋喃衍生物
    • US06864283B2
    • 2005-03-08
    • US10203918
    • 2001-02-16
    • Tatsuo HigaJunichi TanakaDolores Garcia Gravalos
    • Tatsuo HigaJunichi TanakaDolores Garcia Gravalos
    • A61K31/341A61K35/56A61P35/00A61P35/02A61P43/00C07D307/22A61K31/34C07D307/02C07F4/28
    • C07D307/22
    • Compounds of formula (I) wherein R1is selected from H, C(═O)R′, P(═O)R′R″, S(═O)R′R″, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, or substituted or unsubstituted aryl; or R1 together with R2 forms a saturated or unsaturated heterocyclic ring; R2 and R3 are each, independently, selected from H, C(═O)R′, P(═O)R′R″, S(═O)R′R″, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, or substituted or unsubstituted aryl; or one of R2 or R3 together with R1 forms a saturated or unsaturated heterocyclic ring; or R2 and R3 together form a saturated or unsaturated heterocyclic ring; R4 is selected from H, C(═O)R′, P(═O)R′R″, S(═O)R′R″, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18, alkynyl, or substituted or unsubstituted aryl, wherein R′ is selected from the group consisting of H, OH, NO2, NH2, SH, CN, halogen, C(═O)H, C(═O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted and unsubstituted aryl; R″ is selected from the group consisting of H, OH, NO2, NH2, SH, CN, halogen, ═O, C(═O)H, C(═O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted and unsubstituted aryl; wherein X1, X2 X3 on formula I are independently placed in any particular position of the chain and independently selected from H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, NHC(O)R′, CN, halogen, ═O, C(═O)H, C(═O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, wherein substituent groups defined by R′ are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, NHC(O)R′, CN, halogen, ═O, C(═O)H, C(═O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaromatic; wherein x is 6 to 20; and wherein the dotted lined is one or several optional double bonds placed in any particular position of the side chain; or pharmaceutically acceptable salts thereof are useful as antitumor compounds and include compound IK-8-73-4 of structure (a) which was isolated from a sponge Pachastrissa sp.
    • 其中R 1选自H,C(= O)R',P(= O)R'R“,S(= O)R'R”,取代或未取代的C 1 -C 18烷基, 取代或未取代的C 2 -C 18烯基,取代或未取代的C 2 -C 18炔基或取代或未取代的芳基; 或R 1与R 2一起形成饱和或不饱和杂环; R 2和R 3各自独立地选自H,C(= O)R',P(= O)R'R“,S(= O)R'R”,取代或未取代的C 1 -C 18烷基, 取代或未取代的C 2 -C 18烯基,取代或未取代的C 2 -C 18炔基或取代或未取代的芳基; 或R 2或R 3中的一个与R 1一起形成饱和或不饱和杂环; 或R 2和R 3一起形成饱和或不饱和杂环; R 4选自H,C(= O)R',P(= O)R'R“,S(= O)R'R”,取代或未取代的C 1 -C 18烷基,取代或未取代的C 2 -C 18 烯基,取代或未取代的C 2 -C 18炔基或取代或未取代的芳基,其中R'选自H,OH,NO 2,NH 2,SH,CN,卤素,C(= O)H,C( C = O)CH 3,CO 2 H,CO 2 CH 3,取代或未取代的C 1 -C 18烷基,取代或未取代的C 2 -C 18烯基,取代或未取代的C 2 -C 18炔基,取代和未取代的芳基; R“选自H,OH,NO 2,NH 2,SH,CN,卤素,= O,C(= O)H,C(= O)CH 3,CO 2 H,CO 2 CH 3,取代或未取代的C1- C18烷基,取代或未取代的C2-C18烯基,取代或未取代的C2-C18